Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia

被引:15
|
作者
Gallegos, Patrick J. [1 ,2 ,3 ]
Frazee, Lawrence A. [2 ,3 ]
机构
[1] Northeastern Ohio Univ Coll Med & Pharm, Dept Pharm Practice, Rootstown, OH 44272 USA
[2] Northeastern Ohio Univ Coll Med & Pharm, Dept Internal Med, Rootstown, OH 44272 USA
[3] Akron Gen Med Ctr, Dept Pharm, Akron, OH USA
来源
PHARMACOTHERAPY | 2008年 / 28卷 / 03期
关键词
lower urinary tract symptoms; LUTS; benign prostatic hyperplasia; BPH; bladder outlet obstruction; anticholinergics; tolterodine; drug therapy;
D O I
10.1592/phco.28.3.356
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lower urinary tract symptoms (LUTS) are commonly associated with benign prostatic hyperplasia (BPH). The LUTS-BPH complex consists of both voiding and storage symptoms that may overlap with overactive bladder symptoms. Drug therapy for men with LUTS may include alpha(1)-antagonists, 5-alpha-reductase inhibitors, combination therapy, and over-the-counter phytotherapy. Anticholinergic agents are effective in relieving overactive bladder symptoms in patients without bladder outlet obstruction. However, anticholinergic therapy has historically been contraindicated in patients with LUTS associated with BPH because of concerns for developing acute urinary retention. To assess the safety and efficacy of anticholinergic therapies for LUTS associated with BPH, a MEDLINE search and a bibliographic search of the English-language literature were conducted. Two nonrandomized, open-label studies; two randomized trials that assessed anticholinergic therapy alone; and eight trials that assessed anticholinergic therapy in combination with an alpha(1)-antagonist were identified. Trials were of short duration (6-12 wks) and included only men with low postvoid residual volumes at baseline. Small nonsignificant changes were seen in objective measures of urinary function. Several trials demonstrated an increase in postvoid residual with anticholinergic therapy, which was statistically significant in two trials. Despite the increase in postvoid residual, rates of acute urinary retention were low and the drugs were well tolerated. Of the five trials that used a validated symptom scoring scale, two demonstrated subjective improvement in urinary function. Men with symptomatic overactive bladder and BPH who are not adequately relieved with alpha(1)-antagonists may benefit from the addition of an anticholinergic agent. Before starting therapy, however, a postvoid residual volume should be measured to measure to rule out baseline urinary retention.
引用
收藏
页码:356 / 365
页数:10
相关论文
共 50 条
  • [41] Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
    Rosen, RC
    Giuliano, F
    Carson, CC
    EUROPEAN UROLOGY, 2005, 47 (06) : 824 - 837
  • [42] Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia
    Cosimo De Nunzio
    Andrea Salonia
    Mauro Gacci
    Vincenzo Ficarra
    World Journal of Urology, 2020, 38 : 2771 - 2779
  • [43] Embolization of prostate arteries in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia
    Stamatiou, K.
    Moschouris, H.
    Kornezos, I.
    Lambrakopoulos, A.
    SCIENTIFIC CHRONICLES, 2016, 21 (02) : 185 - 196
  • [44] Noninvasive assessment of prostatic obstruction in elderly men with lower urinary tract symptoms associated with benign prostatic hyperplasia
    van Venrooij, GEPM
    Eckhardt, MD
    Boon, TA
    UROLOGY, 2004, 63 (03) : 476 - 480
  • [45] Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia
    De Nunzio, Cosimo
    Giglio, Simona
    Stoppacciaro, Antonella
    Gacci, Mauro
    Cirombella, Roberto
    Luciani, Emidio
    Tubaro, Andrea
    Vecchione, Andrea
    ONCOTARGET, 2017, 8 (31) : 50904 - 50910
  • [46] A prospective study of Rezum (Water Vapor Thermal Therapy) for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
    Bliucukis, R.
    Skov-Jeppesen, S. M.
    Lund, L.
    SCANDINAVIAN JOURNAL OF UROLOGY, 2019, 53 : 3 - 3
  • [47] Commentary on tolterodine for men with benign prostatic hyperplasia and lower urinary tract symptoms
    O'Leary, Michael P.
    JOURNAL OF UROLOGY, 2008, 179 (05): : S86 - S86
  • [48] Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
    Garimella, Pranav S.
    Fink, Howard A.
    MacDonald, Roderick
    Wilt, Timothy J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (04):
  • [49] Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms
    Thomas C.A.
    Chuang Y.-C.
    Giannantoni A.
    Chancellor M.B.
    Current Urology Reports, 2006, 7 (4) : 266 - 271
  • [50] The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia
    Dreikorn, K
    WORLD JOURNAL OF UROLOGY, 2002, 19 (06) : 426 - 435